KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $474.6 million.

  • Jazz Pharmaceuticals' Free Cash Flow rose 22.34% to $474.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.5 million, marking a year-over-year decrease of 53.93%. This contributed to the annual value of $1.4 billion for FY2024, which is 27.13% up from last year.
  • Jazz Pharmaceuticals' Free Cash Flow amounted to $474.6 million in Q3 2025, which was up 162.84% from -$755.3 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Free Cash Flow high stood at $474.6 million for Q3 2025, and its period low was -$755.3 million during Q2 2025.
  • For the 3-year period, Jazz Pharmaceuticals' Free Cash Flow averaged around $232.8 million, with its median value being $316.9 million (2023).
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Free Cash Flow surged by 742.36% in 2022, and later crashed by 332.93% in 2025.
  • Jazz Pharmaceuticals' Free Cash Flow (Quarterly) stood at $167.8 million in 2021, then skyrocketed by 98.22% to $332.6 million in 2022, then slumped by 52.72% to $157.2 million in 2023, then skyrocketed by 145.04% to $385.3 million in 2024, then climbed by 22.34% to $474.6 million in 2025.
  • Its Free Cash Flow stands at $474.6 million for Q3 2025, versus -$755.3 million for Q2 2025 and $415.9 million for Q1 2025.